Company intelligence / Profile preview
Avidicure
Oegstgeest, Zuid-Holland, Netherlandsavidicure.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Avidicure is developing AVC-Boosters, a new multifunctional antibody modality for cancer treatment. Their lead product, AVC-S-101, is in pre-clinical development for NSCLC and other solid tumors. The company plans to start first-in-man studies in Q4 2026.
- Therapeutic areas
- Oncology
- Modalities
- Multifunctional antibodiesdual agonistic avidity-engineered antibodies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Avidicure.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avidicure.